Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retigabine IR Extension Study in Adults With Partial-Onset Seizures
NCT01336621Phase 3Completed
- Sponsor
- GSK
- Start
- Feb 2011
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of retigabine in focal onset seizure, sponsored by GSK. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (TESAEs) up to 5.8 years, Number of Participants With AEs and SAEs up to 2.6 years and 18 more. Started Feb 2011; status: completed.
02
Drugs
retigabine
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT01336621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01336621.